Oral Semaglutide Compounding Faces Regulatory Crackdown After Hims & Hers Initiative

The regulatory landscape for compounded oral semaglutide has shifted dramatically from ambiguity to coordinated federal enforcement, culminating in a 2026 FDA announcement of intent to take action against non-FDA-approved GLP-1 drugs. What unfolded around Hims & Hers Health and its short-lived oral semaglutide offering did not occur in a single regulatory moment but unfolded over time, moving from regulatory ambiguity and manufacturer pressure to coordinated federal enforcement by 2025 and early 2026.

By 2024, GLP-1 receptor agonists had transformed obesity and diabetes care, with semaglutide and tirzepatide producing consistent, clinically meaningful weight loss and significant cardiometabolic benefits. Demand exploded while supply lagged, leading to prolonged shortages and prices exceeding $1,000 per month. During this period, the FDA continued to list certain GLP-1 products as being in shortage, which allowed compounding pharmacies to prepare compounded versions of otherwise approved drugs when commercial supply could not meet patient need.

Against that backdrop, Hims & Hers Health expanded into GLP-1 therapy, with the company's early 2024 offering of compounded injectable semaglutide supplied by partner pharmacies. The inflection point came when Hims introduced a compounded oral semaglutide tablet for weight loss—a product that did not exist in FDA-approved form at obesity-level dosing. Oral peptide delivery presents well-documented scientific challenges, and Novo Nordisk had spent years developing proprietary technology and clinical data to bring oral semaglutide to market for diabetes.

Throughout 2024, Novo Nordisk applied sustained pressure across multiple fronts, raising concerns with regulators about compounded GLP-1 safety, stability and bioavailability, particularly for oral formulations lacking proprietary absorption mechanisms. The company signaled its willingness to escalate beyond traditional civil remedies, with the prospect of criminal referral beginning to loom.

In late 2024 and into 2025, the FDA began formally declaring GLP-1 shortages resolved. Those determinations carried legal consequences—once the shortage predicate disappeared, so did the statutory basis for routine compounding. By spring 2025, most GLP-1 compounding outside narrow, documented medical necessity became presumptively unlawful. The FDA made clear that affordability, convenience, or patient preference were insufficient justifications, and compounded products that were "essentially copies" of FDA-approved drugs were no longer tolerated.

Enforcement followed in September 2025, when the Food and Drug Administration, working with HHS, issued dozens of warning letters targeting compounding pharmacies, telehealth platforms and manufacturers marketing GLP-1 products. The focus was not only on compounding practices, but on marketing conduct—claims suggesting equivalence, predictability of outcomes, or parity with FDA-approved drugs.

That enforcement posture culminated in February 2026, when the FDA publicly stated its intent to take action against non-FDA-approved GLP-1 drugs. The announcement triggered widespread concern among patients and providers relying on compounded therapies. The GLP-1 compounding environment today bears little resemblance to the one that existed just two years earlier, with the legal landscape shifting from unsettled in 2024 to clearly defined by 2026.